The latest announcement is out from Innovent Biologics ( (HK:1801) ).
Innovent Biologics announced that its new drug application for ipilimumab injection, combined with sintilimab, has been accepted by China’s National Medical Products Administration and granted Priority Review designation for treating colon cancer. This represents a significant milestone for Innovent, reinforcing its leadership in cancer immunotherapy. The acceptance is based on successful Phase 3 clinical trial results, which indicated improved pathologic complete response rates for patients, potentially reducing recurrence rates and improving long-term prognosis for those with MSI-H/dMMR colon cancer.
More about Innovent Biologics
Innovent Biologics is a biopharmaceutical company focusing on the development, manufacturing, and commercialization of high-quality biologics. The company specializes in cancer immunotherapy products and aims to provide innovative treatment solutions through collaboration and cutting-edge research.
YTD Price Performance: 1.31%
Average Trading Volume: 37,740
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.79B
See more insights into 1801 stock on TipRanks’ Stock Analysis page.